Previous 10 | Next 10 |
Received U.S. FDA Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Jelmyto Launch on Track for June 1, 2020 Reported UGN-102 Phase 2b Trial Interim Data with 65% Complete Response at Three ...
Conference Call and Webcast Scheduled for Thursday, May 7, 2020 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced...
59% Complete Response in patients with low-grade upper tract urothelial cancer Kaplan-Meier analysis, based on interim data, estimated 12-month durability at 84% Results supported recent U.S. FDA expedited approval of Jelmyto ™ as the first non-surgical treatment for ...
Urogen Pharma Ltd. ( URGN ) is now a commercial biotechnology company that designs and develops therapies for urological pathologies. It was founded in 2004, and while technically incorporated in Israel, URGN's corporate offices are located in Princeton, New Jersey. The company had 173 employe...
Edison Nation (NASDAQ: EDNT ) +169% on over $10M order . More news on: Edison Nation, Inc., Soligenix, Inc., Atossa Therapeutics, Inc., Stocks on the move, , Read more ...
Approval Based on Phase 3 Trial Results Showing a Complete Response Rate of 58% Median Duration of Response Has Not Been Reached Therapy Provides an Effective, Kidney-Sparing Option for Patients With This Rare and Difficult-To-Treat Cancer First-in-Class Approval Valida...
The FDA approves UroGen Pharma's ( URGN -9.0% ) Jelmyto (mitomycin gel) for the treatment of low-grade upper tract urothelial cancer (cancer of the lining of the urinary system), a rare cancer that occurs in 6K - 8K Americans each year. More news on: UroGen Pharma Ltd., Healthcare stoc...
UroGen Pharma Ltd. (NASDAQ: URGN ) announces positive preliminary data from a Phase 2b clinical trial evaluating UGN-102 (mitomycin) for intravesical (administered directly into the bladder) solution in patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG NMIB...
Complete Response (CR) Rate of 65% at Three Months Of those with CR, 97% and 85% of Patients Remained Free of Disease at Six and Nine Months Follow-Up, Respectively Detailed Results Presentation to be Shared Virtually via American Urological Association (AUA) in mid-May ...
Experienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients de...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...